CD19/BCMA CAR T-cells

Phase 1Cell therapy

CChengdu Ucello Biotechnology Co., Ltd.

CD19/BCMA CAR T-cells is one of 22 small molecule programs targeting Hemolytic Anemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemolytic AnemiaActive, not recruiting

Hemolytic AnemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Hemolytic Anemia

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Rituxan

2 3

Neoral

Novartis

Phase 3

1 4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Fostamatinib Bid

RRigel Pharmaceuticals

Phase 3

2 6

HMPL-523

HHutchison Medipharma Limited

Phase 3

1 7

Imbruvica

PPharmacyclics LLC.

Phase 2

2 8

Brukinsa

BBeOne Medicines

Phase 2

1 9

Rayos

RRoxane Laboratories

Phase 2

1 10

Ergamisol

WWim Janssens

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2037

Phase 1Not yet recruiting

CAR-T

NCT07266337

Clinical

Trials by Indication[1]

CAR-T1 trial

CD19/BCMA CAR-T for SLE

Not yet recruiting·CChengdu Ucello Biotechnology Co., Ltd.·Phase 1·NCT07266337·24 enrolled

Hemolytic Anemia1 trial

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Unknown status·ZZhejiang University·Phase 1·NCT05263817·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CD19/BCMA CAR T-cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19/BCMA CAR T-cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19/BCMA CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chengdu Ucello Biotechnology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: CChengdu Ucello Biotechnology Co., Ltd.

CD19/BCMA CAR T-cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2037

Trials by Indication[1]

CAR-T1 trial

Hemolytic Anemia1 trial

References

Drug Info

Quick Facts

Related News